• UW BIOFAB: a force for reproducible science

    UW BIOFAB: a force for reproducible science

    This article was written by Renske Dyedov (UW) Key to advancing any new scientific discovery is the ability for researchers to independently repeat the experiments that led to it. In science today, particularly biology, the lack of reproducibility between experiments is a major problem that slows scientific progress, wastes resources and time, and erodes the […]

  • Deep learning reveals how proteins interact

    Deep learning reveals how proteins interact

    A team led by scientsts in the Baker lab has combined recent advances in evolutionary analysis and deep learning to build three-dimensional models of how most proteins in eukaryotes interact. This breakthrough has significant implications for understanding the biochemical processes that are common to all animals, plants, and fungi. This open-access work appears in Science. […]

  • COVID-19 vaccine with IPD nanoparticles meets Phase 1/2 trial goals

    COVID-19 vaccine with IPD nanoparticles meets Phase 1/2 trial goals

    This report was written and translated into English by SK bioscience. (Image: SK bioscience) SK bioscience (CEO Jae-yong Ahn) announced on November 4th that the company has confirmed a positive immune response and safety in the final analysis result of the phase I/II clinical trial of the COVID-19 vaccine candidate, ‘GBP510,’ co-developed with the Institute […]

  • Baker lab joins USAID’s $125M project to detect emerging viruses

    Baker lab joins USAID’s $125M project to detect emerging viruses

    To better identify and prevent future pandemics, the University of Washington has become a partner in a five-year global, collaborative agreement with the U.S. Agency for International Development. The newly launched Discovery & Exploration of Emerging Pathogens – Viral Zoonoses, or DEEP VZN project, has approximately $125 million in anticipated funding and will be led […]

  • Dr. Berger wins additional WRF translational funding

    Dr. Berger wins additional WRF translational funding

    Washington Research Foundation (WRF) has awarded a $700,000 phase three technology commercialization grant to Stephanie Berger, Ph.D., to support the development of an oral biologic for inflammatory bowel disease (IBD). Berger, a translational investigator at the Institute for Protein Design, received two previous grants totaling $300,500 from WRF for this work. IBD affects roughly three […]

  • On the passing of Tachi Yamada

    On the passing of Tachi Yamada

    Tadataka “Tachi” Yamada MD, KBE served as the Advisory Board Chair of our Institute since its founding almost ten years ago. His tremendous mentorship helped us in innumerable ways to grow from a single-PI Institute founded by David Baker to a group of five faculty and almost 200 scientists and staff.   Tachi also helped […]

  • RoseTTAFold: Accurate protein structure prediction accessible to all

    RoseTTAFold: Accurate protein structure prediction accessible to all

    Today we report the development and initial applications of RoseTTAFold, a software tool that uses deep learning to quickly and accurately predict protein structures based on limited information. Without the aid of such software, it can take years of laboratory work to determine the structure of just one protein. With RoseTTAFold, a protein structure can be […]

  • Annual Report 2021

    Annual Report 2021

    From our deep-learning research to our new clinical trials, we are pleased to present this overview of the progress made at the Institute for Protein Design during the past year. 2021 Annual Report

  • Dr. Roy awarded WRF translational funding

    Dr. Roy awarded WRF translational funding

    Washington Research Foundation (WRF) has awarded a $250,000 phase 2 technology commercialization grant to Anindya Roy, Ph.D., to further develop a novel miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF). Roy, an acting instructor in David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD), is building on positive results […]

  • Two nanoparticle vaccines enter clinical trials

    Two nanoparticle vaccines enter clinical trials

    Two different candidate vaccines developed by researchers at the Institute for Protein Design recently entered human clinical trials. GBP510, a candidate COVID-19 vaccine, is undergoing a combined Phase 1/2 trial. Flu-Mos-v1, a candidate mosaic influenza vaccine, is undergoing Phase 1 testing. Candidate COVID-19 vaccine Our SARS-CoV-2 vaccine candidate was created with structure-based vaccine design techniques […]